Rat Kidney biomarkers: 613‐APS (renal)

Abstract

Multiplex measurement of rat kidney cytokines in serum and urine using the Fluorokine® MAP assayJane Schmidt Ph.D, Michael Rynning, Richard Fuerstenberg R&D Systems, Inc., Minneapolis, MNDrug toxicity can result in major organ damage to the kidneys. The traditional methods for monitoring drug‐induced nephrotoxicity in toxicology studies include measurement of serum creatinine and blood urea nitrogen levels, but in recent years more sensitive kidney biomarkers have emerged. The PCK rat is a recently identified rodent model of polycystic kidney disease that can be used as a model for general kidney disease or damage. We measured TIM‐1/KIM‐1, FABP‐1, Lipocalin‐2, Cystatin C, and Osteopontin in serum and urine from normal (Sprague Dawley) and PCK rats using the Fluorokine MAP Rat Kidney Toxicity Panel and observed a significant increase of TIM‐1/KIM‐1 and Lipocalin‐2 in the PCK rat serum compared to normal rat serum. We also observed statistically significant differences for Lipocalin‐2 and Cystatin C in PCK urine when compared to normal urine. Fluorokine Multianalyte Profiling (MAP) kits are bead‐based multiplex immunoassays designed for use on Luminex® 100/200™, Bio‐Rad® Bio‐Plex® analyzers and offer the ability to quantify multiple analytes simultaneously with less user time, less sample volume, and lower cost per result compared to conventional ELISAs. Five biomarkers can be measured in a user‐defined multiplex using the Rat Kidney Toxicity Panel. The assay is fully validated for accurate, precise, and reproducible results in rat serum, plasma, and urine.